

# Philip Wells

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11026042/publications.pdf>

Version: 2024-02-01

32  
papers

8,716  
citations

430874  
18  
h-index

414414  
32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

7949  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.8	58
2	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A cross-sectional study using the Canadian Community Health Survey. Cancer Medicine, 2021, 10, 7601-7609.	2.8	1
3	Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 195-208.	1.7	7
4	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1143-1163.	0.8	531
5	Regarding the necessity of an updated meta-analysis on the prognostic value of serum biomarkers in patients with pulmonary embolism. Thrombosis Research, 2019, 176, 8-10.	1.7	2
6	An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears. Trials, 2019, 20, 694.	1.6	9
7	Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. Seminars in Thrombosis and Hemostasis, 2018, 44, 341-347.	2.7	12
8	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	1.4	5
9	Cast versus functional brace in the rehabilitation of patients treated for an ankle fracture: protocol for the UK study of ankle injury rehabilitation (AIR) multicentre randomised trial. BMJ Open, 2018, 8, e027242.	1.9	15
10	Scoring Systems for Diagnosis of Acute Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2017, 43, 479-485.	2.7	3
11	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	1.5	45
12	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. American Journal of Medicine, 2017, 130, 482.e1-482.e9.	1.5	9
13	Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2017, 5, 18-24.e1.	1.6	15
14	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.8	51
15	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	3.4	8
16	DVT Management and Outcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.8	23
17	Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry. European Journal of Internal Medicine, 2016, 32, 53-59.	2.2	12
18	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.8	4,060

#	ARTICLE	IF	CITATIONS
19	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	3.4	48
20	Graduated compression stockings to treat acute leg pain associated with proximal DVT. Thrombosis and Haemostasis, 2014, 112, 1137-1141.	3.4	48
21	The diagnosis and treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2013, 2013, 457-463.	2.5	60
22	Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. Journal of Medical Economics, 2012, 15, 817-828.	2.1	17
23	The Diagnosis of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2012, 38, 691-701.	2.7	18
24	Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thrombosis and Haemostasis, 2010, 104, 760-770.	3.4	51
25	Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Thrombosis and Haemostasis, 2010, 104, 498-503.	3.4	59
26	Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thrombosis and Haemostasis, 2009, 101, 197-200.	3.4	71
27	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood, 2008, 112, 4432-4436.	1.4	103
28	An Evaluation of D-Dimer in the Diagnosis of Pulmonary Embolism. Annals of Internal Medicine, 2006, 144, 812.	3.9	159
29	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 349, 631-639.	27.0	728
30	The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism. Thrombosis and Haemostasis, 2003, 90, 829-834.	3.4	19
31	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. Thrombosis and Haemostasis, 2000, 83, 416-420.	3.4	1,417
32	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine, 1999, 340, 901-907.	27.0	1,052